A new analysis of outcomes of adjuvant chemotherapy compared with observation in 1,544 patients with upper tract urothelial carcinoma (UTUC) from 15 centres who had undergone radical nephroureterectomy demonstrated no difference in overall survival between the two groups (HR 1.14, 95%CI 0.91–1.43; P = 0.268). The benefit from adjuvant chemotherapy in these patients remains unclear and dedicated trials and improved patient selection criteria are still needed.
References
Necchi, A. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. http://dx.doi.org/10.1111/bju.14020 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. Benefit of adjuvant chemotherapy in UTUC unclear. Nat Rev Urol 14, 639 (2017). https://doi.org/10.1038/nrurol.2017.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.170